Menu
Menu
Find answers from the depths of your data with a powerful, accurate application that lets you analyze, visualize, and explore genome results in one streamlined workflow.
SOPHiA DDM™ for Whole Genome Sequencing (WGS) combines rapid, scalable computing with advanced analytics to detect complex variants and support confident interpretation.
One pipeline for secondary and tertiary analysis, delivering comprehensive detection and streamlined interpretation.
NVIDIA GPUs power heavy workloads, with parallel samples run on Microsoft Azure nodes for fast, scalable genome analysis.
Dedicated AI agents detect constitutional and mosaic variants in genomic and mitochondrial DNA, including SNVs, CNVs, RoH, and SVs.
Boost lab efficiency with a single streamlined FASTQ-to-report workflow. All variant detection and interpretation steps are powered by the SOPHiA DDM™ Platform, giving you full control over your data and samples.
SOPHiA DDM™ for WGS uncovers the full landscape of genomic variation with high sensitivity and precision. From structural variants and RoH to CNVs and mitochondrial changes, integrated signal analysis ensures reliable detection across every layer of the genome.
SOPHiA DDM™ streamlines tertiary analysis by unifying diverse annotation sources, applying updated ACMG guidelines, and leveraging community knowledge for variant interpretation. Robust, phenotype-driven prioritization ensures the most relevant variants are ranked with accuracy and efficiency, while intuitive visualization supports clear interpretation of results.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
